Charles Schwab
NRIX icon

Charles Schwab’s Nurix Therapeutics NRIX Stock Holding History

Charles Schwab’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.2M Sell
833,296
-90,743
-10% -$1.55M ﹤0.01% 1825
2026
Q1 		$14.3M Sell
924,039
-41,853
-4% -$694K ﹤0.01% 1925
2025
Q4 		$18.3M Buy
965,892
+101,512
+12% +$1.46M ﹤0.01% 1803
2025
Q3 		$7.99M Buy
864,380
+257,253
+42% +$2.67M ﹤0.01% 2212
2025
Q2 		$6.92M Buy
607,127
+25,061
+4% +$271K ﹤0.01% 2186
2025
Q1 		$6.91M Buy
582,066
+9,232
+2% +$154K ﹤0.01% 2130
2024
Q4 		$10.8M Buy
572,834
+61,114
+12% +$1.4M ﹤0.01% 1984
2024
Q3 		$11.5M Sell
511,720
-111,684
-18% -$2.53M ﹤0.01% 1960
2024
Q2 		$13M Sell
623,404
-18,786
-3% -$293K ﹤0.01% 1908
2024
Q1 		$9.44M Buy
642,190
+19,893
+3% +$214K ﹤0.01% 2015
2023
Q4 		$6.42M Buy
622,297
+53,721
+9% +$368K ﹤0.01% 2203
2023
Q3 		$4.47M Buy
568,576
+184,617
+48% +$1.69M ﹤0.01% 2309
2023
Q2 		$3.84M Sell
383,959
-881
-0.2% -$8.98K ﹤0.01% 2339
2023
Q1 		$3.42M Buy
384,840
+1,925
+0.5% +$20.1K ﹤0.01% 2367
2022
Q4 		$4.2M Buy
382,915
+8,342
+2% +$101K ﹤0.01% 2306
2022
Q3 		$4.88M Buy
374,573
+84,114
+29% +$1.33M ﹤0.01% 2226
2022
Q2 		$3.68M Buy
290,459
+20,404
+8% +$231K ﹤0.01% 2317
2022
Q1 		$3.78M Buy
270,055
+6,415
+2% +$114K ﹤0.01% 2406
2021
Q4 		$7.63M Buy
263,640
+3,880
+1% +$118K ﹤0.01% 2140
2021
Q3 		$7.78M Buy
259,760
+129,872
+100% +$4.01M ﹤0.01% 2153
2021
Q2 		$3.45M Buy
129,888
+16,953
+15% +$498K ﹤0.01% 2531
2021
Q1 		$3.51M Buy
112,935
+36,064
+47% +$1.36M ﹤0.01% 2459
2020
Q4 		$2.53M Buy
76,871
+4,662
+6% +$154K ﹤0.01% 2532
2020
Q3 		$2.52M Buy
+72,209
New +$1.82M ﹤0.01% 2417

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Charles Schwab's NRIX Position: Q2 2026 in Review

Charles Schwab reduced its Nurix Therapeutics (NRIX) stake by 9.8% in Q2 2026, selling an estimated $1.55M and leaving 833,296 shares worth $20.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1825.

Charles Schwab first reported a position in NRIX in Q3 2020 and has held it in 24 quarters since. 212 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • Charles Schwab held 833,296 shares of Nurix Therapeutics worth $20.2M as of Q2 2026.
  • Charles Schwab sold 90,743 Nurix Therapeutics shares in Q2 2026, an estimated $1.55M.
  • Nurix Therapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #1825 holding.
  • Charles Schwab first reported a position in Nurix Therapeutics in Q3 2020 and has held it in 24 quarters since.
  • 212 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.